13309ONC-392-001OpenSafety, Pharmacokinetics (PK), and Efficacy of ONC-392 as a Single Agent and in Combination with Pembrolizumab in Advanced Solid Tumors and NSCLC: An Open Label Phase IA/IB StudyNCT04140526IndustryAdultTreatmentIBreast; Lung; Other Skin; PancreasHe, RuthGeorgetown University Medical Center; Lombardi Comprehensive Cancer CenterPhase I/SarcomaOncology GroupLombardi Comprehensive Cancer Center (LCCC)2021R3.1 Build 22 <a href="https://advarra.com" target="_blank">© 2024 Advarra, Inc.</a>